Financial Survey: Pharming Group (NASDAQ:PHAR) vs. Adlai Nortye (NASDAQ:ANL)

Adlai Nortye (NASDAQ:ANL) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Profitability

This table compares Adlai Nortye and Pharming Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Pharming Group	0.30%	0.46%	0.25%

Insider and Institutional Ownership

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Adlai Nortye and Pharming Group”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	N/A	N/A	-$51.87 million	N/A	N/A
Pharming Group	$297.20 million	3.88	-$11.84 million	($0.01)	-1,681.00

Pharming Group has higher revenue and earnings than Adlai Nortye.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Adlai Nortye and Pharming Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1	1	0	0	1.50
Pharming Group	0	2	2	0	2.50

Pharming Group has a consensus target price of $38.00, indicating a potential upside of 126.06%. Given Pharming Group’s stronger consensus rating and higher probable upside, analysts plainly believe Pharming Group is more favorable than Adlai Nortye.

Summary

Pharming Group beats Adlai Nortye on 9 of the 10 factors compared between the two stocks.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.